FluoroPharma Announces License Agreement With Massachusetts General Hospital
Posted on: Friday, 28 March 2008, 09:01 CDT
FluoroPharma, the molecular imaging group of QuantRx Biomedical, has entered into a license agreement with Massachusetts General Hospital for the development and commercialization of agents for diagnosis and treatment of Alzheimer's disease.
The licensed technologies, which were co-developed by FluoroPharma and Massachusetts General Hospital (MGH) scientists, target multiple biological processes associated with Alzheimer's disease. According to the available sources, currently, there is no single diagnostic test that proves a person has Alzheimer's.
Kundakovic, FluoroPharma's president, said: "The technology has the potential to be highly effective due to the agents enhanced accumulation in the brain. In combination with high resolution PET imaging, these agents may provide valuable information in patients where early diagnostic and therapeutic information is likely to have the greatest benefit."
Source: Datamonitor
Related Articles
- Imaging Agent May Help ID Alzheimer's
- QuantRx(R) Announces FluoroPharma, Inc. To Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents
- FluoroPharma, Inc. To Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents
- Avid Radiopharmaceuticals Presents Clinical Results of Novel Amyloid Imaging Agents at the 2008 International Conference on Alzheimer's Disease (ICAD)
- QuantRx Announces Expansion of Its Molecular Imaging Technology Platform for Development of Diagnosis and Treatment Agents for Alzheimer's Disease (AD)
- FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease (AD)
- Neurochem's New Agent Will Become the Clinical Gold Standard for the Treatment of Alzheimer's Disease in 2008
- Alzheimer's Drug Shows Promise in Treating Nerve Agent Poisoning
- Schering AG and Avid Radiopharmaceuticals to Develop Novel Approach for Early Diagnostic Imaging of Alzheimer's Disease
- Humanetics Signs Exclusive License With Mount Sinai School of Medicine to Develop Oral Agent to Combat Alzheimer's Disease
 |
 |
User Comments (0)
RSS Feeds